Opinion

Video

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.

Related Videos
Medcast series
2 experts in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.